Avita Medical, Inc. · NASDAQ:RCEL
Avita Medical — Q3 2026 Earnings Presentation
13 slides from Avita Medical's earnings presentation, Nov 9, 2026
Slide 1: AVITA Medical Third Quarter 2026 Briefing
rsonal use only November 2026 AVITA Medical Third Quarter 2026 Briefing Cary Vance, President and CEO David O’Toole, CFO (ASX: AVH, NASDAQ: RCEL)
Slide 2: Forward-Looking Statements & Legal Disclaimers
Forward-Looking Statements & Legal Disclaimers 2024.Q4 v9 This presentation and the accompanying oral commentary may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are predictions and subject to significant risks and un
Slide 3: Strong third quarter revenue and cash use of $0.6 million; increased 2026 guidance
AVITA delivered strong third quarter revenue and cash use of $0.6 million; further increase to 2026 full year revenue guidance Revenue Cash use rsonal use only in USD millions in USD millions Q3 Q4 Q1 Q2 Q3 2025 2025 2026 2026 2026 $6.2 $5.1 $9.9 $3.2 $0.6 $17.1 $17.6 $19.3 $21.7 $26.1 Q3 2025 Q4 20
Slide 4: RECELL volume growth drove a 20% sequential increase in quarterly revenue
RECELL volume growth drove a 20% sequential increase in quarterly revenue Portfolio quarter-over-quarter Total U.S. RECELL volume by quarter rsonal use only in USD millions in units +20.9% Q2 2026 Q3 2026 +11.3% US RECELL® $18.5 $22.4 ~20% +12% +1.8% Cohealyx ® $1.7 $2.1 ~21% PermeaDerm ® $0.6 $0.6
Slide 5: Revenue growth and higher gross margin reduced quarterly net loss by 53%
Revenue growth and higher gross margin reduced the quarterly net loss by 53% Key figures Q3 Q3 Change vs Q2 Change vs rsonal use only in USD millions 2026 2025 prior year 2026 Q2 2026 Revenue $26.1 $17.1 +53% $21.7 +20% Gross profit margin 84% 81.3% +270 BPS 81.9% +210 BPS Operating expenses $24.6 $
Slide 6: Higher 2026 guidance supports approximately 30% full-year revenue growth
Higher 2026 guidance supports approximately 30% full-year revenue growth Revenue rsonal use only Updated full year 2026 guidance in USD millions Forecast +30%* Revenue expected +11% +28% to grow: +46% $92M to $94M +35% Previously $86M-89M 35 Expect to achieve cash flow breakeven in: Q4 2026 2022 202
Slide 7: National Medicare payment and simpler coding support broader RECELL access in 2027
National Medicare payment and simpler coding support broader RECELL access in 2027 The Centers for Medicare & Medicaid Services (CMS) finalized national Medicare physician rsonal use only payment for RECELL procedures and simplified CPT coding effective January 1, 2027 Bundles harvest, preparation,
Slide 8: Clinical evidence is building across AVITA Medical's acute wound care portfolio
Clinical evidence is building across AVITA Medical’s acute wound care portfolio Regional conferences highlight rsonal use only growing portfolio evidence 26x presentations accepted across the 2026 American Burn Association regional conference program Includes: 1 PREPARE 2 REBUILD 3 RESTORE • RECELL
Slide 9: PermeaDerm matched allograft outcomes while reducing product cost by 70%
In study data announced in Q3, PermeaDerm matched allograft outcomes while reducing product cost by 70% Multi-center randomized controlled study (n = 40; 11 U.S. burn centers) rsonal use only 70% Lower Product Cost 95.7% Mean Reduction in Comparable graft take and healing Per %TBSA* Treated Preparat
Slide 10: Portfolio data addresses shorter stays and lower treatment costs
Our portfolio data addresses two critical hospital priorities: shorter stays and lower treatment costs RECELL supports significantly Cohealyx supports faster graft- PermeaDerm provides an alternative shorter hospital length of stay (LOS) readiness to allograft rsonal use only Reduced LOS by 36% comp
Slide 11: RECELL GO reaches leading hospitals across three Australian states
RECELL GO reaches leading hospitals across three Australian states In just three months, first cases have expanded from Western Australia to leading children’s hospitals in Victoria and Queensland. rsonal use only AVITA Medical | November 2026 11
Slide 12: AVITA Medical enters Q4 with growth, improving cash performance and expanding adoption
AVITA Medical enters Q4 with growth, improving cash performance and expanding adoption rsonal use only Continued Raised FY 2026 PermeaDerm On track to business revenue guidance demonstrates achieve cash flow momentum in Q3, for a second comparable breakeven in Q4 with 53% year on sequential time cli
Slide 13: rsonal use only
rsonal use only